全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...
PLOS ONE  2013 

Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses

DOI: 10.1371/journal.pone.0077879

Full-Text   Cite this paper   Add to My Lib

Abstract:

Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus (ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100% mortality by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss and morbidity, and 100% survival. Treatment on days 2 or 3 post-infection resulted in 40% and 20% survival, respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.

 References

[1]  Fenner F, Wittek R, Dumbell K (1989) The Orthopoxviruses. California: Academic Press.
[2]  Moss B (2001) Poxviridae: the viruses and their replication. In: BN Fields[!(surname)!]PM Howley. Fields Virology. Philadelphia: Lippincott Raven Publishers. pp. 2849-2883.
[3]  WHO (1980) The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva. 1-122 p.
[4]  Amorosa VK, Isaacs SN (2003) Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome. Clin Infect Dis 37: 426-432. doi:10.1086/375823. PubMed: 12884168.
[5]  Thorne CD, Hirshon JM, Himes CD, McDiarmid MA (2003) Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guideline and policies and procedures. Ann Emerg Med 42: 665-680. doi:10.1016/S0196-0644(03)00629-2. PubMed: 14581920.
[6]  LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB (2002) Smallpox research activities: U.S. interagency collaboration, 2001. Emerg Infect Dis 8: 743-745. doi:10.3201/eid0807.020032. PubMed: 12095449.
[7]  Nalca A, Rimoin AW, Bavari S, Whitehouse CA (2005) Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41: 1765-1771. doi:10.1086/498155. PubMed: 16288402.
[8]  De Clercq E, Neyts J (2004) Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev Med Virol 14: 289-300. doi:10.1002/rmv.439. PubMed: 15334537.
[9]  Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, vanLavieren R et al. (2006) Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748. doi:10.1038/nature04295. PubMed: 16341204.
[10]  Wittek R (2006) Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 10: 193-201. doi:10.1016/j.ijid.2005.12.001. PubMed: 16564720.
[11]  Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE et al. (2009) In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother 53: 1007-1012. doi:10.1128/AAC.01044-08. PubMed: 19075062.
[12]  Yang G, Pevear DC, Davies MH, Collett MS, Bailey T et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79: 13139-13149. doi:10.1128/JVI.79.20.13139-13149.2005. PubMed: 16189015.
[13]  Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE et al. (2007) Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 51: 689-695. doi:10.1128/AAC.00879-06. PubMed: 17116683.
[14]  Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R et al. (2007) Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 51: 4118-4124. doi:10.1128/AAC.00762-07. PubMed: 17724153.
[15]  Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW et al. (2008) Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79: 121-127. doi:10.1016/j.antiviral.2008.03.005. PubMed: 18479761.
[16]  Lanier R, Trost L, Tippin T, Lampert B, Robertson A et al. (2010) Development of CMX001 for the Treatment of Poxvirus Infections. Viruses 2: 2740-2762. doi:10.3390/v2122740. PubMed: 21499452.
[17]  Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY et al. (2007) Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 76: 768-773. PubMed: 17426185.
[18]  CDC (2007) Household transmission of vaccinia virus from contact with a military smallpox vaccinee--Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 56: 478-481. PubMed: 17510612.
[19]  Vora S, Damon I, Fulginiti V, Weber SG, Kahana M et al. (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46: 1555-1561. doi:10.1086/587668. PubMed: 18419490.
[20]  CDC (2009) Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 58: 532-536. PubMed: 19478722.
[21]  CDC (2009) Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 58: 1204-1207. PubMed: 19893480.
[22]  Mortimer PP (2003) Can postexposure vaccination against smallpox succeed? Clin Infect Dis 36: 622-629. doi:10.1086/374054. PubMed: 12594644.
[23]  Paran N, Suezer Y, Lustig S, Israely T, Schwantes A et al. (2009) Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 199: 39-48. doi:10.1086/595565. PubMed: 19012492.
[24]  Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G (2006) Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol 87: 2917-2921. doi:10.1099/vir.0.82068-0. PubMed: 16963750.
[25]  Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE (1987) Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329: 545-546. doi:10.1038/329545a0. PubMed: 3498904.
[26]  Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921. doi:10.1126/science.8009221. PubMed: 8009221.
[27]  Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA (1996) Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 70: 7103-7107. PubMed: 8794356.
[28]  Flexner C, Hügin A, Moss B (1987) Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330: 259-262. doi:10.1038/330259a0. PubMed: 3118219.
[29]  Gherardi MM, Ramírez JC, Esteban M (2003) IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 84: 1961-1972. doi:10.1099/vir.0.19120-0. PubMed: 12867626.
[30]  Shors T, Kibler KV, Perkins KB, Seidler-Wulff R, Banaszak MP et al. (1997) Complementation of vaccinia virus deleted of the E3L gene by mutants of E3L. Virology 239: 269-276. doi:10.1006/viro.1997.8881. PubMed: 9434718.
[31]  Brandt TA, Jacobs BL (2001) Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75: 850-856. doi:10.1128/JVI.75.2.850-856.2001. PubMed: 11134298.
[32]  Legrand FA, Verardi PH, Chan KS, Peng Y, Jones LA et al. (2005) Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci U S A 102: 2940-2945. doi:10.1073/pnas.0409846102. PubMed: 15705716.
[33]  Kibler KV, Shors T, Perkins KB, Zeman CC, Banaszak MP et al. (1997) Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol 71: 1992-2003. PubMed: 9032331.
[34]  Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL (2006) Inhibition of PKR by RNA and DNA viruses. Virus Res 119: 100-110. PubMed: 16704884.
[35]  Legrand FA, Verardi PH, Jones LA, Chan KS, Peng Y et al. (2004) Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol 78: 2770-2779. doi:10.1128/JVI.78.6.2770-2779.2004. PubMed: 14990697.
[36]  Earl P, Moss B (1991) Generation of recombinant vaccinia viruses. In: RE KingstonDD MooreG. Seidman, Ausubel FM BR. New York: Current Protocols in Molecular Biology: Wiley. pp. 16.16.11-16.16.17.
[37]  Blasco R, Sisler JR, Moss B (1993) Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 67: 3319-3325. PubMed: 8497053.
[38]  Chen W, Drillien R, Spehner D, Buller RM (1992) Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 187: 433-442. doi:10.1016/0042-6822(92)90445-U. PubMed: 1546448.
[39]  Moss B, Earl P (1991) Expression of proteins in mammalian cells using vaccinia virus vectors. Overview of the vaccinia virus epression system. In: RE KingstonDD MooreJG Seidman, Ausubel FM BR. Current protocols in molecular biology. pp. 16.16.11-16.16.17.
[40]  Wallace GD, Buller RM (1985) Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. Lab Anim Sci 35: 41-46. PubMed: 2984458.
[41]  Jentarra GM, Heck MC, Youn JW, Kibler K, Langland JO et al. (2008) Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 26: 2860-2872. doi:10.1016/j.vaccine.2008.03.044. PubMed: 18455281.
[42]  Kaplan C (1989) Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch Virol 106: 127-139. doi:10.1007/BF01311044. PubMed: 2669685.
[43]  Xiang Y, Moss B (1999) IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc Natl Acad Sci U S A 96: 11537-11542. doi:10.1073/pnas.96.20.11537. PubMed: 10500212.
[44]  Liu G, Zhai Q, Schaffner DJ, Wu A, Yohannes A et al. (2004) Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol Med Microbiol 40: 201-206. doi:10.1016/S0928-8244(03)00358-4. PubMed: 15039095.
[45]  Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75: 3185-3196. doi:10.1128/JVI.75.7.3185-3196.2001. PubMed: 11238845.
[46]  Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev 127: 157-182. doi:10.1111/j.1600-065X.1992.tb01413.x. PubMed: 1354650.
[47]  Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189. PubMed: 14525967.
[48]  Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R et al. (2009) Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 385: 11-21. doi:10.1016/j.virol.2008.11.015. PubMed: 19100593.
[49]  Nalca A, Nichols DK (2011) Rabbitpox: a model of airborne transmission of smallpox. J Gen Virol 92: 31-35. doi:10.1099/vir.0.026237-0. PubMed: 20965981.
[50]  Giavedoni LD, Jones L, Gardner MB, Gibson HL, Ng CT et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A 89: 3409-3413. doi:10.1073/pnas.89.8.3409. PubMed: 1565633.
[51]  Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA (1990) Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 20: 157-161. doi:10.1002/eji.1830200123. PubMed: 2106440.
[52]  Cheers C, Janas M, Ramsay A, Ramshaw I (1999) Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection. Immunol Cell Biol 77: 324-330. doi:10.1046/j.1440-1711.1999.00829.x. PubMed: 10457199.
[53]  Raggo C, Habermehl M, Babiuk LA, Griebel P (2000) The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma. J Gen Virol 81: 2665-2673. PubMed: 11038378.
[54]  Giavedoni L, Ahmad S, Jones L, Yilma T (1997) Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol 71: 866-872. PubMed: 8995602.
[55]  Anderson KP, Fennie EH, Yilma T (1988) Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-gamma treatment at primary immunization. J Immunol 140: 3599-3604. PubMed: 2834443.
[56]  Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A et al. (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259: 1739-1742. doi:10.1126/science.8456300. PubMed: 8456300.
[57]  Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D et al. (1996) Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 184: 557-567. doi:10.1084/jem.184.2.557. PubMed: 8760809.
[58]  Harris N, Buller RM, Karupiah G (1995) Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 69: 910-915. PubMed: 7529336.
[59]  Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C et al. (1993) Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261: 1445-1448. doi:10.1126/science.7690156. PubMed: 7690156.
[60]  Parker S, Nuara A, Buller RM, Schultz DA (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2: 17-34. doi:10.2217/17460913.2.1.17. PubMed: 17661673.
[61]  Alcamí A, Smith GL (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633-4639. PubMed: 7609027.
[62]  Symons JA, Adams E, Tscharke DC, Reading PC, Waldmann H et al. (2002) The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J Gen Virol 83: 2833-2844. PubMed: 12388820.
[63]  Reading PC, Smith GL (2003) Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77: 9960-9968. doi:10.1128/JVI.77.18.9960-9968.2003. PubMed: 12941906.
[64]  Bloom DC, Edwards KM, Hager C, Moyer RW (1991) Identification and characterization of two nonessential regions of the rabbitpox virus genome involved in virulence. J Virol 65: 1530-1542. PubMed: 1847470.
[65]  Guerra S, Aracil M, Conde R, Bernad A, Esteban M (2005) Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis. J Virol 79: 2133-2140. doi:10.1128/JVI.79.4.2133-2140.2005. PubMed: 15681416.
[66]  Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M (2006) Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 116: 11-20. doi:10.1016/j.virusres.2005.08.008. PubMed: 16214252.
[67]  Parker S, Siddiqui AM, Painter G, Schriewer J, Buller RM. (2010) Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics. Viruses 2: 1918-1932. doi:10.3390/v2091918. PubMed: 21994714.
[68]  Buller RM, Owens G, Schriewer J, Melman L, Beadle JR et al. (2004) Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318: 474-481. doi:10.1016/j.virol.2003.11.015. PubMed: 14972516.
[69]  Esteban DJ, Buller RM (2005) Ectromelia virus: the causative agent of mousepox. J Gen Virol 86: 2645-2659. doi:10.1099/vir.0.81090-0. PubMed: 16186218.
[70]  Fenner F (1949) Mouse-pox; infectious ectromelia of mice; a review. J Immunol 63: 341-373. PubMed: 15398116.
[71]  Sakala IG, Chaudhri G, Buller RM, Nuara AA, Bai H et al. (2007) Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J Virol 81: 3346-3353. PubMed: 17229697.
[72]  Mossman K, Upton C, Buller RM, McFadden G (1995) Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208: 762-769. doi:10.1006/viro.1995.1208. PubMed: 7747448.
[73]  Smith VP, Alcami A (2002) Inhibition of interferons by ectromelia virus. J Virol 76: 1124-1134. doi:10.1128/JVI.76.3.1124-1134.2002. PubMed: 11773388.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133